- Home
- KF vs IMUX Comparison
KF vs IMUX Comparison
Compare KF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- IMUX
- Stock Information
- Founded
- KF 1984
- IMUX 2016
- Country
- KF United States
- IMUX United States
- Employees
- KF N/A
- IMUX N/A
- Industry
- KF Investment Managers
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- IMUX Health Care
- Exchange
- KF Nasdaq
- IMUX Nasdaq
- Market Cap
- KF 98.6M
- IMUX 102.2M
- IPO Year
- KF N/A
- IMUX N/A
- Fundamental
- Price
- KF $19.79
- IMUX $1.12
- Analyst Decision
- KF
- IMUX Strong Buy
- Analyst Count
- KF 0
- IMUX 7
- Target Price
- KF N/A
- IMUX $12.67
- AVG Volume (30 Days)
- KF 18.4K
- IMUX 572.2K
- Earning Date
- KF 01-01-0001
- IMUX 05-07-2025
- Dividend Yield
- KF N/A
- IMUX N/A
- EPS Growth
- KF N/A
- IMUX N/A
- EPS
- KF N/A
- IMUX N/A
- Revenue
- KF N/A
- IMUX N/A
- Revenue This Year
- KF N/A
- IMUX N/A
- Revenue Next Year
- KF N/A
- IMUX N/A
- P/E Ratio
- KF N/A
- IMUX N/A
- Revenue Growth
- KF N/A
- IMUX N/A
- 52 Week Low
- KF $18.30
- IMUX $0.92
- 52 Week High
- KF $25.56
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- KF 35.47
- IMUX 46.81
- Support Level
- KF $20.93
- IMUX $1.18
- Resistance Level
- KF $21.29
- IMUX $1.28
- Average True Range (ATR)
- KF 0.37
- IMUX 0.07
- MACD
- KF -0.12
- IMUX -0.00
- Stochastic Oscillator
- KF 1.98
- IMUX 6.00
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.